Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

An International, Retrospective Study of Off-Label Biologic Use in the Treatment of Hypereosinophilic Syndromes

The Journal of Allergy and Clinical Immunology In Practice(2022)10.1016/j.jaip.2022.02.006Source: DataRank Database

An International, Retrospective Study of Off-Label Biologic Use in the Treatment of Hypereosinophilic Syndromes is a research paper published in The Journal of Allergy and Clinical Immunology In Practice (2022). On theSindex it has a DataRank of 0. It has been cited 37 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access37 citations

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (8 grants)Impact (FWCI 4.92)OA: bronzeTopics (44)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (24)

Florence Roufosse ORCID,Sa A. Wang ORCID,Srđan Verstovšek ORCID,Sandy Durrani ORCID,Marc E. Rothenberg ORCID

Live enrichment

PubMed:35181548 PMC:PMC9086180 OpenAlex:https://openalex.org/W4213356723

National Institutes of Health

Grant: T32AI083216

Fonds De La Recherche Scientifique - FNRS

Grant: FC 54372

National Institutes of Health

Grant: 5T32AI083216-04

Northwestern University Allergy Immunology Research Program (NUAIR)

American Partnership for Eosinophilic Disorders

Johns Hopkins University

Sanofi

AstraZeneca

GlaxoSmithKline

FWCI

4.92

Citation Percentile

1.0%

Citation Trend

2022

2023

2024

2025

2026

bronzeLicense: Elsevier TDM

journalhttps://www.jaci-inpractice.org/article/S2213-2198(22)00132-5/pdf

publisherhttps://www.jaci-inpractice.org/article/S2213-2198(22)00132-5/pdf

publisherhttps://api.elsevier.com/content/article/PII:S2213219822001325?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2213219822001325?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.jaip.2022.02.006

Fields of Study

Eosinophilic Disorders and SyndromesEosinophilic EsophagitisAsthma and respiratory diseases0301 basic medicine0303 health sciences03 medical and health sciencesAlemtuzumabBiological ProductsGlucocorticoidsHumansHypereosinophilic SyndromeInterleukin-5Off-Label UseRetrospective Studies

MeSH Terms

AlemtuzumabBiological ProductsGlucocorticoidsHumansRetrospective StudiesInterleukin-5Hypereosinophilic SyndromeOff-Label Use

Keywords

MepolizumabMedicineBenralizumabOmalizumabAlemtuzumabHypereosinophilic syndromeInternal medicineEosinophiliaDosingImmunologyEosinophilImmunoglobulin EAsthmaBiologicEosinophilic Granulomatosis With PolyangiitisBiological ProductsOff-Label UseHumansInterleukin-5Pathologie maladies infectieusesGlucocorticoidsRetrospective Studies

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being